In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Merck Serono Bounce Back?

Executive Summary

Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.

You may also be interested in...



Rossetti Sets A High Bar At Merck Serono

Once-moribund Merck Serono has hired former Merck R&D exec Luciano Rossetti to re-energize its attempts at an R&D turnaround. A deal with Pfizer for the PD-L1 inhibitor avelumab has the company off to a good re-start.

Deal Watch: Merck KGAA Boosts Pharma Unit’s Reach And Capabilities With Sigma-Aldrich Buy

Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.

Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint

By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel